Last reviewed · How we verify

NCT06212440

Clinical Application of Multi-modal Sentinel Lymph Node Staining Method in Breast Cancer Patients After Neoadjuvant Chemotherapy

Completed NA Last updated 13 March 2025
What this trial tests

NA trial testing Radioactive Isotope (RI) Mapping in Sentinel Lymph Node Biopsy in 348 participants. Completed in 2 October 2024.

Timeline
4 May 2021
Primary endpoint
14 August 2024
2 October 2024

Quick facts

Lead sponsorNational Cancer Center, Korea
PhaseNA
StatusCompleted
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingnone
Primary purposediagnostic
Enrollment348
Start date4 May 2021
Primary completion14 August 2024
Estimated completion2 October 2024
Sites2 locations across South Korea

Drugs / interventions tested

Conditions studied

Sponsor

National Cancer Center, Korea

Who can join

20 and older, female only, with Sentinel Lymph Node Biopsy or Neoadjuvant Therapy. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This clinical trial aimed to confirm the effectiveness of sentinel lymph node surgery by determining the lymph node identification rate using multimodal sentinel lymph node marker methods in patients with advanced breast cancer undergoing neoadjuvant chemotherapy (NAC).

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Sentinel Lymph Node Biopsy

Currently open trials in the same condition.

Other National Cancer Center, Korea trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06212440.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing